Skip to main content
main-content

05.05.2016 | Review Article | Ausgabe 8/2016

Supportive Care in Cancer 8/2016

Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer—a systematic review

Zeitschrift:
Supportive Care in Cancer > Ausgabe 8/2016
Autoren:
Ricardo Fernandes, Sasha Mazzarello, Brian Hutton, Risa Shorr, Habeeb Majeed, Mohammed FK Ibrahim, Carmel Jacobs, Michael Ong, Mark Clemons

Abstract

Background

Taxane acute pain syndrome (TAPS) is characterized by myalgias and arthralgias starting 24–48 h after taxane-based chemotherapy and lasting for 5–7 days. Relatively little is known about its incidence and impact on quality of life.

Objectives

A systematic review was conducted evaluating the incidence of TAPS in breast cancer patients receiving taxane-based chemotherapy.

Methods

Embase, Cochrane, and Ovid MEDLINE were searched from 1947 to July 2015. Data was sought from randomized controlled trials (RCTs), prospective and retrospective observational studies. Two reviewers independently screened citations and full text articles. Outcomes of interest were the incidence of TAPS and its impact on quality of life.

Results

Of 980 citations identified, 51 relevant studies (27,007 patients) were included. Data came from RCTs (12,357 patients), retrospective (6566 patients) and prospective observational studies (6210 patients). Study sample sizes ranged from 14 to 4149 patients (median 152). Given the significance between study heterogeneity, a meta-analysis was not performed. The incidence of TAPS varied between taxanes: paclitaxel (median 13.1 %, range 0.9–86 %), docetaxel (median 10.5 %, range 3.6–70 %), and nab-paclitaxel (26 %, range 14–43 %). In the metastatic setting, median incidence was 30 % (range 5.4–73 %), compared with 11.3 % (range 0.9–86 %) in the adjuvant setting. Three out of eight studies assessing quality of life demonstrated pain interference with daily activities.

Conclusions

The incidence of TAPS varies between taxanes, regimens, and disease settings. In order to identify patients at the greatest risk of TAPS, and hence optimize its prevention and management, standardized methods of diagnosing and measuring TAPS are needed.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt e.Med zum Sonderpreis bestellen!

Sichern Sie sich jetzt Ihr e.Med-Abo und sparen Sie 50 %!

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 8/2016

Supportive Care in Cancer 8/2016 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.